INTERVIEW: Regeneron CEO Schleifer looks to diabetic market for Eylea growth
This article was originally published in Scrip
Executive Summary
Quarterly sales of Regeneron Pharmaceuticals’ eye treatment Eylea fell short of Wall Street expectations, marking a first for the fast-growing drug.